Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.

Add Yahoo as a preferred source to see more of our stories on Google. Demis Hassabis speaks during the 56th annual World Economic Forum (WEF) meeting in Davos, Switzerland, January 20, 2026.

Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is pairing ...

This study will update and extend How People Learn: Brain, Mind, Experience, and School (2000) by examining the research that has emerged across various disciplines that focus on the study of learning ...

Machine learning is the ability of a machine to improve its performance based on previous results. Machine learning methods enable computers to learn without being explicitly programmed and have ...

Nonverbal learning disorder (NVLD), also known as nonverbal learning disability, is a neurological condition which typically emerges during childhood but can persist through adulthood. It is marked by ...

Google DeepMind, the artificial intelligence company behind the popular AlphaFold tool, has published the next generation of the application’s protein structure prediction software. The new tool can ...